Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call.

Kiniksa Pharmaceuticals will host a conference call on July 29, 2025, to discuss its Q2 2025 financial results and portfolio execution. The company focuses on developing novel therapies for cardiovascular diseases, a niche market with high growth potential. A replay of the webcast will be available 48 hours post-event. However, the press release lacks specific financial performance or portfolio updates, leaving investors to wait for the webcast.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has scheduled its second quarter 2025 financial results conference call and webcast for Tuesday, July 29, 2025, at 8:30 a.m. Eastern Time. The company will discuss its Q2 2025 financial performance and recent portfolio developments [1].

Investors can access the live webcast through the Investors & Media section on Kiniksa's website. For telephone participation, interested parties must pre-register to receive dial-in details. A replay will be available on the company's website within 48 hours after the event [1].

Kiniksa Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases, with a focus on cardiovascular indications. The company's portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation [2].

Analysts expect Kiniksa to report a 40.5% increase in revenue to $145.218 million for the period ending June 30, 2025, compared to $103.39 million a year ago. The mean analyst estimate for earnings is 18 cents per share [2].

The company has also announced that its Phase 2/3 clinical trial of KPL-387, a potential treatment for recurrent pericarditis, is now actively recruiting participants. KPL-387 is a monoclonal antibody targeting IL-1R1 to inhibit IL-1α and IL-1β signaling [3].

Kiniksa Pharmaceuticals is expected to present at two major investor conferences in June 2025: the Jefferies 2025 Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference [4].

The upcoming conference call is an opportunity for investors to gain insights into Kiniksa's financial performance and portfolio execution. However, the press release lacks specific financial performance or portfolio updates, leaving investors to wait for the webcast.

References:
[1] https://www.stocktitan.net/news/KNSA/kiniksa-pharmaceuticals-to-report-second-quarter-2025-financial-mph482qd2f9r.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TM190:0-kiniksa-pharmaceuticals-international-plc-expected-to-post-earnings-of-18-cents-a-share-earnings-preview/
[3] https://www.myocarditisfoundation.org/kpl-387-clinical-trial-recurrent-pericarditis/
[4] https://www.stocktitan.net/news/KNSA/